Orexigen Obesity Drug Trials Successful in 3 Studies
Orexigen Therapeutics Inc. said Monday that in three large late-stage studies its obesity-drug candidate Contrave met its main goals and also surpassed a Food and Drug Administration requirement for effectiveness. The San Diego-based company said it plans to seek FDA approval for Contrave in early 2010.

  • Digg
  • StumbleUpon
  • Reddit
  • RSS


Post a Comment